A Pilot Trial of Ipilimumab With Nivolumab for Participants With Resected Stages IIIB/IIIC/ IV Melanoma
Latest Information Update: 06 May 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 10 Apr 2024 Primary endpoints got amended as safety (adverse events) endpoint has been removed and relapse-free survival has been added, hence trial focus has been shifted to Tu from Ar.
- 11 Aug 2022 Status changed from active, no longer recruiting to completed.
- 18 Jan 2022 Planned End Date changed from 1 Apr 2021 to 1 Feb 2022.